These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18272062)

  • 1. [Foxa2, a new player in the development of dopaminergic neurons in Parkinson disease].
    Epelbaum J
    Med Sci (Paris); 2008 Feb; 24(2):117. PubMed ID: 18272062
    [No Abstract]   [Full Text] [Related]  

  • 2. Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival.
    Lee HS; Bae EJ; Yi SH; Shim JW; Jo AY; Kang JS; Yoon EH; Rhee YH; Park CH; Koh HC; Kim HJ; Choi HS; Han JW; Lee YS; Kim J; Li JY; Brundin P; Lee SH
    Stem Cells; 2010 Mar; 28(3):501-12. PubMed ID: 20049900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lmx1a and Lmx1b cooperate with Foxa2 to coordinate the specification of dopaminergic neurons and control of floor plate cell differentiation in the developing mesencephalon.
    Nakatani T; Kumai M; Mizuhara E; Minaki Y; Ono Y
    Dev Biol; 2010 Mar; 339(1):101-13. PubMed ID: 20035737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Grafted dopaminergic neurons are targeted by the disease process in Parkinson's disease].
    Lelan F; Damier P
    Med Sci (Paris); 2009 Jan; 25(1):15-6. PubMed ID: 19154684
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopamine and Parkinson's disease: is the killer in the house?
    Chesselet MF
    Mol Psychiatry; 2003 Apr; 8(4):369-70. PubMed ID: 12740592
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.
    Xu J; Kao SY; Lee FJ; Song W; Jin LW; Yankner BA
    Nat Med; 2002 Jun; 8(6):600-6. PubMed ID: 12042811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease.
    Hirsch EC; Hunot S; Damier P; Brugg B; Faucheux BA; Michel PP; Ruberg M; Muriel MP; Mouatt-Prigent A; Agid Y
    Adv Neurol; 1999; 80():9-18. PubMed ID: 10410697
    [No Abstract]   [Full Text] [Related]  

  • 8. Programmed cell death and Parkinson's disease.
    Burke RE
    Mov Disord; 1998; 13 Suppl 1():17-23. PubMed ID: 9613714
    [No Abstract]   [Full Text] [Related]  

  • 9. [Dopaminergic neurons and clinical neuropsychiatry].
    Ferrari E
    Acta Neurol (Napoli); 1992; 14(4-6):241-64. PubMed ID: 1293968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does autophagy worsen or improve the survival of dopaminergic neurons?
    Pasquali L; Ruggieri S; Murri L; Paparelli A; Fornai F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S24-7. PubMed ID: 20123552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent progresses on the modulation of estrogen to dopaminergic neurons].
    Liu B; Xie JX
    Sheng Li Ke Xue Jin Zhan; 2001 Jul; 32(3):259-61. PubMed ID: 12545804
    [No Abstract]   [Full Text] [Related]  

  • 12. Neurochemical correlates of parkinsonism. Role of dopaminergic lesions.
    Hirsch EC; Herrero MT
    Adv Neurol; 1997; 74():119-26. PubMed ID: 9348407
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of the dopaminergic lesion in Parkinson's disease by CSF markers.
    LeWitt PA
    Adv Neurol; 1993; 60():544-7. PubMed ID: 8420188
    [No Abstract]   [Full Text] [Related]  

  • 14. Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease?
    Michel PP; Ruberg M; Hirsch E
    Sci STKE; 2006 Apr; 2006(332):pe19. PubMed ID: 16639033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress to dopaminergic neurons as models of Parkinson's disease.
    Gille G; Hung ST; Reichmann H; Rausch WD
    Ann N Y Acad Sci; 2004 Jun; 1018():533-40. PubMed ID: 15240412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuronal pathology in Parkinson's disease.
    Schulz JB; Falkenburger BH
    Cell Tissue Res; 2004 Oct; 318(1):135-47. PubMed ID: 15365812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease.
    Anastasia A; de Erausquin GA; Wojnacki J; Mascó DH
    J Neurochem; 2007 Nov; 103(4):1542-52. PubMed ID: 17854351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotrophic factors and Parkinson's disease: the emergence of a new player?
    Dauer W
    Sci STKE; 2007 Nov; 2007(411):pe60. PubMed ID: 17986711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism of monoamine toxicity in Parkinson's disease: hypothetical cell death model.
    Jimenez del Rio M; Velez-Pardo C
    Med Hypotheses; 2000 Feb; 54(2):269-74. PubMed ID: 10790763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.
    Grace AA
    Mov Disord; 2008; 23 Suppl 3():S560-9. PubMed ID: 18781673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.